Lime Delivers Record Revenue and Profitability, Positive Free Cash Flow in 2024
18.2.2025 12:00:00 CET | Business Wire | Press release
Global Micromobility Leader’s Business Momentum Delivers Profitable GrowthGross Bookings of $810 Million, Net Revenue of $686 MillionAdjusted EBITDA Exceeds $140 Million, Up From $94 Million in 2023Free Cash Flow Positive for Second Consecutive Year
Lime, the world’s largest shared electric vehicle company, today announced record unaudited financial results for 2024, reflecting continued operating and financial momentum as the Company executes against its mission to build a future where transportation is shared, affordable and carbon-free.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218624910/en/
Two young women ride Lime electric bikes through a city. (Photo: Business Wire)
Full Year 2024 Financial Highlights (unaudited)
- Gross bookings of $810 million, reflecting growth of 31% versus 2023
- Net revenue of $686 million, an increase of 32% compared to 2023
- Fourth consecutive year of 30%+ topline growth
- Adjusted EBITDA1 over $140 million, up from $94 million in 2023, representing year-over-year growth of 49%
- Adjusted EBITDA margin1 over 20%, representing more than 200 basis points of expansion versus prior year
- Free cash flow positive for second consecutive year
“2024 was an exceptional year for Lime and our global leadership is evident both operationally and financially with strong results across all of our key metrics,“ said Wayne Ting, CEO. “We grew profits faster than revenue in 2024, posting another record year of results through serving more than 24 million riders in hundreds of communities around the world and bringing Lime to more cities globally. As we continue to expand our fleet, our permit win and retention rates demonstrate that Lime remains the clear choice for cities seeking to reduce traffic congestion and meet carbon emission goals. While we saw record demand in 2024, we’re just scratching the surface of micromobility’s potential to transform cities and better connect people. Our proven execution, combined with these global tailwinds, position Lime for durable growth for years to come.”
Full Year 2024 Operating Highlights and Metrics
- Provided more than 200 million rides in 2024, up 30% from 2023, equating to more than six rides per second, with more than 24 million riders taking a trip in 2024
- Surpassed 750 million lifetime rides
- Won over 90% of competitive permits to operate in top tier cities
- Expanded to more than 20 new cities globally, including launches into two new countries, Japan and Greece
- Expanded average operational fleet by nearly 20% to over 270,000 vehicles globally
Lime also deepened its management team in 2024, with key executive appointments who draw on decades of experience at Fortune 500 companies. Chief Legal Officer Susie Giordano brings more than 30 years of experience in capital markets, governance, compliance and M&A, including serving as the Corporate Secretary for Intel Corporation. Incoming Chief Technology Officer Jon Jenkins joined Lime from Amazon, with prior roles including Head of Engineering at Pinterest.
“As we continue to advance our mission, we are driving consistent growth through fleet expansion, increased rider utilization, geographic expansion and continuous innovation,” said Ann Gugino, CFO. “We are well above a ‘rule of 40’ company and are intently focused on scaling our unit economics. In 2024, we invested for growth, while simultaneously delivering increased profitability and positive free cash flow. Importantly, our team has a proven track record of strong execution and Lime has an exciting roadmap and multiple avenues for growth in 2025 and beyond.”
Environmental sustainability remains a key focus for Lime and it continues to make an impact on reducing carbon emissions in cities. Last year, riders avoided an estimated 20,000 metric tons of CO2 emissions, spared an estimated 2.2 million gallons of gas (8.5M liters) from being consumed and replaced more than an estimated 43 million car trips with two-wheeled, emissions-free rides. Lime also continues to make meaningful strides in reducing its own carbon intensity across Scopes 1, 2 and 3 emissions. Its most recent carbon inventory measuring 2023 impact showed a 59.5% reduction from its 2019 baseline. Lime plans to release its 2024 carbon inventory later this spring.
About Lime
Lime’s mission is to build a future where transportation is shared, electric and carbon-free. As a leading global provider of shared electric vehicles, Lime partners with cities to deploy electric bikes and scooters to serve any trip under five miles. A Time Magazine 100 Most Influential Companies and Fast Company Brand that Matters, Lime has powered more than 750 million rides across five continents, spurring a new generation of clean alternatives to car ownership. Learn more at li.me.
_____________________
1 The company’s unaudited financial results communicated herein reflect certain non-GAAP financial measures. In particular, the Company presents adjusted EBITDA which is defined as earnings before interest, income taxes, depreciation and amortization, and excludes certain items that affect comparability from period to period or are not indicative of our ongoing operating performance, and Adjusted EBITDA margin, which is calculated as Adjusted EBITDA/Net Revenue. The non-GAAP financial measures provided in this press release are not a substitute for the company’s financial results prepared in accordance with U.S. GAAP and may be different from similarly-titled non-GAAP measures used by other companies. Unaudited financial results communicated herein are subject to change upon finalization of the audit.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218624910/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom